WEDNESDAY, Dec. 22 (HealthDay News) -- U.S. Food and Drug
Administration approval of Gardasil (human papillomavirus vaccine)
has been widened to include prevention of anal cancer and
associated precancerous lesions, the agency said Wednesday in a
Human papillomavirus (HPV) is associated with about 90 percent
of the estimated 5,300 cases of anal cancer diagnosed in the United
States each year, the FDA said, citing statistics from the American
Cancer Society. More women are diagnosed than men.
The latest approval for Gardasil covers people aged 9 to 26. The
vaccine was previously approved for the same age group to prevent
cervical, vulvar and vaginal cancers in females, and for genital
warts among both sexes.
Gardasil won't prevent development of anal precancerous lesions
already present at the time of vaccination, the FDA said.
The most common adverse reactions to the vaccine include
fainting, injection-site pain, headache, nausea and fever.
To learn more about anal cancer, visit the U.S.
National Cancer Institute.